On the other hand, the indication for allo‐HCT in CR1 in AML patients with NPM1 mutation and FLT3‐ITD low allelic ratio, who also belong to the ELN favorable risk group remains controversial.9, 24. Here, NPM1 is linked to acute myeloid leukemia.